会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE
    • 作为BCR-ABL激酶的抑制剂的苯甲酰胺嘧啶衍生物
    • US20080306100A1
    • 2008-12-11
    • US12042235
    • 2008-03-04
    • Amala Kishan KOMPELLABhujanga Rao ADIBHATLA KALI SATYASreenivas RACHAKONDANannapaneni VENKAIAH CHOWDARY
    • Amala Kishan KOMPELLABhujanga Rao ADIBHATLA KALI SATYASreenivas RACHAKONDANannapaneni VENKAIAH CHOWDARY
    • C07D401/04A61K31/506C07C381/00A61P35/00
    • C07C323/62C07C233/66C07C279/18C07C317/44C07D213/82C07D401/04C07D401/14
    • The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC50; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML.The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans. The compound of formula I, also known as AN-019, is: This invention relates to a process for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula (I)) starting from 4-methyl-2-nitro-aniline (formula (II)) through intermediates (3-trifluoromethylsulfonyl)-N-[4-methyl-3-nitrophenyl]-benzamide (formula (III)), (3-trifluoromethylsulfonyl)-N-[3-amino-4-methylphenyl]-benzamide (formula (IV)) and (3-trifluoromethylsulfonyl)-N-[3-guanidino-4-methylphenyl]-benzamide (formula (V)). This invention also relates to processes for the preparation of these intermediates. The compound of formula (I), also known as AN-024, is:
    • 本发明涉及可用于制备新型苯基氨基嘧啶衍生物,新型苯基氨基嘧啶衍生物的新中间体。 含有新型苯基氨基嘧啶衍生物的药物组合物及其制备方法。 本发明特别涉及通式(I)的新型苯基嘧啶胺衍生物。 式1的新化合物可用于治疗慢性骨髓性白血病(CML)。 由于IC50; 这些分子的191个值在0.1至10.0nm的范围内,这些新化合物潜在地可用于治疗CML。 本发明涉及(3,5-双三氟甲基)-N- [4-甲基-3-(4-吡啶-3-基 - 嘧啶-2-基氨基) - 苯基] - 苯甲酰胺(式I)的具体形式,方法 用于制备它们,含有这种晶形的药物组合物,以及它们在人体中作为抗肿瘤剂的用途。 式I化合物,也称为AN-019,是:本发明涉及制备(3-三氟甲基磺酰基)-N- [4-甲基-3-(4-吡啶-3-基 - 嘧啶-2-基氨基 (3-三氟甲基磺酰基)-N- [4-甲基-3-硝基苯基] - 苯甲酰胺,由4-甲基-2-硝基 - 苯胺(式(II))开始制备) - 苯基] - 苯甲酰胺 (式(III)),(3-三氟甲基磺酰基)-N- [3-氨基-4-甲基苯基] - 苯甲酰胺(式(IV))和(3-三氟甲基磺酰基)-N- [3-胍基-4-甲基苯基] - 苯甲酰胺(式(V))。 本发明还涉及制备这些中间体的方法。 式(I)化合物,也称为AN-024,为: